We are pleased to announce that Journal of Clinical and Translational Hepatology (JCTH) has received its first impact factor – 4.108 – in the Journal Citation Report released by Clarivate Analytics on June 30, 2021. JCTH now ranks 42nd among 92 journals in the Gastroenterology and Hepatology category and is in the second quartile (Q2) in the category (Fig. 1). Moreover, JCTH has also received its first CiteScore – 6.7 – released by Elsevier on June 4, 2021 and ranks 16th among 62 hepatology journals according to that evaluation system (Fig. 2).
JCTH, which is owned by the Second Affiliated Hospital of Chongqing Medical University and published by Xia & He Publishing Inc., publishes articles on both basic and clinical liver disease research. The translational application of basic science is a distinctive feature of the Journal. JCTH was launched in 2013 and has been included in PubMed Central and PubMed since July 2015, in Scopus since May 2020, and in SCIE since November 2020.1
We would like to take this opportunity to express our heartfelt gratitude to our staff, associate editors, editorial board members, early-career editors, reviewers, authors, and readers, for their dedication, contributions, and attention to the Journal.
Having the first impact factor being over 4 and CiteScore being 6.7 is encouraging and inspiring. However, we recognize these achievements as representing a solid foundation from which we will continue to push forth our efforts toward greater academic goals. In these efforts, we will continue to be rigorous in both academic quality and ethical standards, ever-striving to bring timely research findings in hepatology to the scientific community as an internationally influential journal.